A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study Meeting Abstract
| Authors: | Jhaveri, K. L.; Lim, E.; Hamilton, E. P.; Saura, C.; Meniawy, T.; Jeselsohn, R.; Beck, J. T.; Kaufman, P. A.; Sammons, S.; Banda, K.; Okera, M.; Yonemori, K.; Harnden, K. K.; Kim, S. B.; Sohn, J.; Ma, C. X.; Aftimos, P. G.; Wang, X. A.; Young, S. R. L.; Beeram, M. |
| Abstract Title: | A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120600155 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.1050 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1050 -- Source: Wos |
